story of the week
β-Thalassemias
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Quality of Life in Sickle Cell Disease and Thalassemia After Stem Cell Transplant or Gene Therapy
- Risk Factors for Endocrine Complications in Transfusion-Dependent Thalassemia Patients on Chelation Therapy With Deferasirox
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
- Luspatercept in Patients With Transfusion-Dependent β-Thalassemia
- Related and Unrelated Donor Transplantation for Β-Thalassemia Major
- Long-Term Sequential Deferiprone and Deferasirox Therapy in Transfusion-Dependent Thalassemia Patients
- Iron Metabolism Under Conditions of Ineffective Erythropoiesis in Beta-Thalassemia
- 2018 Top Stories in Benign Hematology: Severe Thalassemias
- Management of Medical Complications Associated With Beta-Thalassemia in Adults
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
β-Thalassemias
N. Engl. J. Med 2021 Feb 25;384(8)727-743, AT Taher, KM Musallam, MD CappelliniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.